title: Restoring the balance: immunotherapeutic combinations for autoimmune disease.
abstract: Autoimmunity occurs when T cells, B cells or both are inappropriately activated, resulting in damage to one or more organ systems. Normally, high-affinity self-reactive T and B cells are eliminated in the thymus and bone marrow through a process known as central immune tolerance. However, low-affinity self-reactive T and B cells escape central tolerance and enter the blood and tissues, where they are kept in check by complex and non-redundant peripheral tolerance mechanisms. Dysfunction or imbalance of the immune system can lead to autoimmunity, and thus elucidation of normal tolerance mechanisms has led to identification of therapeutic targets for treating autoimmune disease. In the past 15 years, a number of disease-modifying monoclonal antibodies and genetically engineered biologic agents targeting the immune system have been approved, notably for the treatment of rheumatoid arthritis, inflammatory bowel disease and psoriasis. Although these agents represent a major advance, effective therapy for other autoimmune conditions, such as type 1 diabetes, remain elusive and will likely require intervention aimed at multiple components of the immune system. To this end, approaches that manipulate cells ex vivo and harness their complex behaviors are being tested in preclinical and clinical settings. In addition, approved biologic agents are being examined in combination with one another and with cell-based therapies. Substantial development and regulatory hurdles must be overcome in order to successfully combine immunotherapeutic biologic agents. Nevertheless, such combinations might ultimately be necessary to control autoimmune disease manifestations and restore the tolerant state.
authors.affiliation: The Immune Tolerance Network, 185 Berry Street #3515, San Francisco, CA 94107, USA.
authors.forename: Dawn E
authors.initials: DE
authors.lastname: Smilek
authors.forename: Mario R
authors.initials: MR
authors.lastname: Ehlers
authors.forename: Gerald T
authors.initials: GT
authors.lastname: Nepom
mesh_terms: D000818:Animals; D001327:Autoimmune Diseases / Q000276:immunology* / Q000628:therapy*; D015551:Autoimmunity / Q000276:immunology; D003131:Combined Modality Therapy; D000939:Epitopes / Q000276:immunology; D006801:Humans; D007108:Immune Tolerance / Q000276:immunology; D007167:Immunotherapy
chemical_list: D000939:Epitopes
keywords: Autoimmune; Biologic; Tolerance